March 1, 2026 5:37 am

Tag: Crohn’s Disease

New Hope for Severe Crohn’s: Breakthrough Drug Targets Scarring

Agomab Therapeutics has launched a groundbreaking clinical trial for ontunisertib, a drug specifically targeting fibrostenosing Crohn’s disease—the severe, scarring form that has limited treatment options. This represents the first targeted therapy designed to address the root cause of intestinal scarring rather than just managing symptoms.

The FMT Study That Didn’t Work: What It Teaches Us About Crohn’s

A recent study tested fecal microbiota transplantation (FMT) for Crohn’s disease with disappointing results—but what can we learn from this setback? While FMT didn’t improve remission rates in 8 weeks, the research offers valuable insights for future treatments and reminds us that progress in IBD research often comes through understanding what doesn’t work.

You Missed

Surgery Remains a Vital Option for Children with IBD: What Parents Need to Know

Surgery Remains a Vital Option for Children with IBD: What Parents Need to Know

February 22, 2026
Barnacle-Inspired "Living Glue" Shows Promise for Healing IBD Gut Wounds

Barnacle-Inspired “Living Glue” Shows Promise for Healing IBD Gut Wounds

February 21, 2026
Global IBD Cases Surge: What New Research Means for Your Health Journey

Global IBD Cases Surge: What New Research Means for Your Health Journey

February 20, 2026
Sanofi's IBD Drug Shows Promise in Long-Term Extension Study: What This Could Mean for Your Treatment Options

Sanofi’s IBD Drug Shows Promise in Long-Term Extension Study: What This Could Mean for Your Treatment Options

February 19, 2026